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through JAK/STAT3 modulation of mitochondrial
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Andre Bilodeau1, Randy Van Der Ploeg1 and Paul Fernyhough1,2Abstract
Background: A luminex-based screen of cytokine expression in dorsal root ganglia (DRG) and nerve of type 1
diabetic rodents revealed interleukin-1 (IL-1α) and IL-1β to be significantly depressed. We, therefore, tested the
hypothesis that impaired IL-1α and IL-1β expression in DRG may contribute to aberrant axon regeneration and
plasticity seen in diabetic sensory neuropathy. In addition, we determined if these cytokines could optimize
mitochondrial bioenergetics since mitochondrial dysfunction is a key etiological factor in diabetic neuropathy.
Results: Cytokines IL-1α and IL-1β were reduced 2-fold (p<0.05) in DRG and/or nerve of 2 and 5 month
streptozotocin (STZ)-diabetic rats. IL-2 and IL-10 were unchanged. IL-1α and IL-1β induced similar 2 to 3-fold
increases in neurite outgrowth in cultures derived from control or diabetic rats (p<0.05). STAT3 phosphorylation on
Tyr705 or Ser727 was depressed in DRG from STZ-diabetic mice and treatment of cultures derived from STZ-
diabetic rats with IL-1β for 30 min raised phosphorylation of STAT3 on Tyr705 and Ser727 by 1.5 to 2-fold (p<0.05).
shRNA-based or AG490 inhibition of STAT3 activity or shRNA blockade of endogenous IL-1β expression completely
blocked neurite outgrowth. Cultured neurons derived from STZ-diabetic mice were treated for 24 hr with IL-1β and
maximal oxygen consumption rate and spare respiratory capacity, both key measures of bioenergetic fidelity that
were depressed in diabetic compared with control neurons, were enhanced 2-fold. This effect was blocked by
AG490.
Conclusions: Endogenous synthesis of IL-1β is diminished in nerve tissue in type 1 diabetes and we propose this
defect triggers reduced STAT3 signaling and mitochondrial function leading to sup-optimal axonal regeneration
and plasticity.
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Peripheral nerve injury is associated with an inflammatory
response at the site of damage that is associated with
enhanced expression of cytokines such as interleukin-1β
(IL-1β), TNF-α and IL-6 [1-3]. Nerve damage, and associ-
ated Wallerian degeneration, causes the secretion of IL-1β
by Schwann cells and invading macrophages leading to a* Correspondence: asaleh@sbrc.ca
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reproduction in any medium, provided the orcascade of events, in part leading to increased expression
of nerve growth factor (NGF) by fibroblasts [4-7]. The in-
duction of NGF provides neurotrophic support for regen-
erating nerve fibers but this inflammatory process also
triggers the development of hyperalgesia [8,9].
Recent studies reveal that IL-1β may directly target
sensory neurons. Adult sensory neurons express recep-
tors for cytokines, such as LIF [10], IL-6 [11] and IL-1β
[12] and these cytokines undergo enhanced expression
within the dorsal root ganglia (DRG) upon nerve damage
[13,14]. IL-1β is synthesized by DRG sensory neurons [12]td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Effect of 2 or 5 month STZ-diabetes on cytokine
levels in rat DRG and sciatic nerve
IL-1α IL-1β IL-10 IL-2
DRG 2 Months
Control 0.97 ± 0.1* 60.35 ± 15.4* 17.53 ± 6.0 4.53 ± 1.38
Diabetes 0.36 ± 0.05 28.38 ± 2.1 12.65 ± 3.6 2.63 ± 0.57
Sciatic nerve
Control 22.64 ± 7.3* 63.93 ± 18.2* 9.78 ± 3.5 3.09 ± 0.28
Diabetes 9.55 ± 3.7 34.05 ± 6.3 13.87 ± 7.1 4.98 ± 0.90
Tibial nerve
Control 25.0 ±1.7 102.4 ± 17.7* 31.79 ± 17.7 4.64 ± 3.04
Diabetes 19.46 ±9.5 45.41 ± 8.5 39.64 ± 3.9 6.12 ±2.53
DRG 5 Months
Control 1.99 ± 0.6* 75.7 ± 10.9* ND 5.99 ± 2.93
Diabetes 0.68 ± 0.1 32.1 ± 5.2 ND 1.93 ± 0.63
Sciatic nerve
Control 15.9 ± 2.5* 64.15 ± 8.1* ND 2.08 ± 0.77
Diabetes 3.6 ± 1.1 25.68 ± 5.3 ND 2.61 ± 1.15
Tibial nerve
Control 17.0 ± 2.46* 105.4 ± 14.8* ND 3.81 ± 1.63
Diabetes 3.4 ± 1.02 30.74 ± 6.6 ND 3.25 ± 0.94
Cytokine protein levels were determined using a Luminex machine with the
BioRad 9-plex cytokine kit and are expressed in pg/mg total protein. A
standard curve was generated for each cytokine and all values were derived
from the linear aspect of the curve. Values are mean ± SD, n=4-6. *P<0.05 vs
diabetic (Students t-Test).
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nerve injury in vivo [7,15] and in vitro [6,16].
The JAK/STAT3 pathway is activated after nerve in-
jury in DRG and motor neurons and maintains neuronal
survival and drives axon regeneration [17-23]. Phosphoryl-
ation on Tyr705 and transcriptional activation of STAT3
is modulated by cytokines, including IL-1β [2,24,25] and
growth factors [26,27]. STAT3 phosphorylation on Ser727
regulates its translocation to the mitochondria and modu-
lates the activity of electron transport Complex I [28-30].
In PC12 cells the interaction of STAT3 phosphorylated on
Ser727 with mitochondria was associated with NGF in-
duction of neurite outgrowth [31].
High ATP consumption by growth cones during motil-
ity instills a need for optimal mitochondrial function to
maintain axon regeneration and plasticity [32,33]. Mito-
chondrial dysfunction has been proposed as a central
mediator of development of many neurodegenerative
diseases [34,35], including neurological and other dis-
eases associated with diabetes [33,36,37]. Recently, we
have demonstrated that sensory neurons of diabetic
rodents exhibit an abnormal mitochondrial phenotype
that contributes to the etiology of diabetic neuropathy
[38,39]. Recent studies reveal reduced cytokine expres-
sion in DRG and nerve of diabetic rodents [40] and the
ability of neuropoietic cytokines to enhance mitochon-
drial bioenergetics [33]. We, therefore, tested the
hypothesis that impaired IL-1β expression in DRG may
contribute to aberrant axon regeneration and plasticity
seen in diabetic sensory neuropathy.
Results
IL-1β protein levels are diminished in DRG and nerve
tissue under a diabetic state
DRG and nerve tissue from 2 or 5 month STZ-induced
diabetic rat cohorts were collected and analyzed for a
panel of cytokines. Table 1 provides data on levels of
IL-1α, IL-1β, IL-10 and IL-2 in DRG, sciatic nerve and
tibial nerve. IL-1α and IL-1β protein levels were signifi-
cantly reduced in lumbar DRG and in sciatic nerve at 2
and 5 months of diabetes (*p<0.05 vs diabetic). IL-1β
protein levels were also significantly reduced in tibial
nerve, however, IL-1α levels were unchanged in tibial
nerve at 2 months. IL-2 and IL-10 were unchanged in
any tissue at 2 and 5 months. At 2 and 5 months, the
diabetic rats were hyperglycemic, exhibited loss of weight
and were hypoalgesic (enhanced thermal withdrawal
latency) compared with age matched control animals
(presented previously in [40]).
IL-1β elevates neurite outgrowth in adult rat sensory
neurons
The ability of IL-1β to modulate adult sensory neuron
phenotype was investigated. Adult rat DRG sensoryneurons derived from normal rats were dissociated and
grown under defined conditions and treated with a range
of IL-1α and IL-1β concentrations for 24 h. Cultures were
fixed, stained for neuron specific β-tubulin III (Figure 1a),
and the levels of total neurite outgrowth were quantified.
These experiments were performed in the presence or
absence of a cocktail of neurotrophic factors. IL-1α and
IL-1β stimulated neurite outgrowth in a dose-dependent
manner under both conditions (Figure 1b, c, d) with a sig-
nificant effect starting at 10 ng/ml for both cytokines
(*p<0.05 vs control). There were three to five fold in-
creases in neurite outgrowth when cultures were grown
without neurotrophic growth factors (Figure 1b and c). In
the presence of growth factors the IL-1β-dependent in-
duction of neurite outgrowth was approximately 2-fold
(Figure 1d). Cultures were then prepared from age
matched control or 3–5 month STZ-induced diabetic
rats and impact of IL-1β (10 ng/ml) on neurite out-
growth was analyzed. Figure 1e shows that IL-1β was
able to elevate neurite outgrowth in DRG neurons from
normal and diabetic rats (*p<0.05 vs control).
IL-1 receptor type 1 and P-STAT3-Tyr705 are expressed in
control rat DRG neurons
We investigated the localization of IL-1 receptor type 1
and P-STAT3-Tyr705, as an indicator of cytokine signaling,
Figure 1 IL-1α and IL-1β significantly increased neurite outgrowth in normal and diabetic neurons. In (a) images of cultures stained for
neuron-specific β-tubulin III are shown for untreated control (Ctl), treated for 24 h with IL-1β (10 ng/ml) or treated with IL-1α (10 ng/ml). Size
marker indicates 100 μm. In (b) is shown total neurite outgrowth of neurons in response to a range of IL-1α concentrations grown for 24 h
under defined conditions without neurotrophic growth factors (GF). Values are means ± SEM (n = 3 replicates); *p < 0.05 vs control (oneway
ANOVA with Dunnett’s test). In (c) is shown total neurite outgrowth of neurons in response to a range of IL-1β concentrations without
neurotrophic growth factors. Values are means ± SEM (n = 3 replicates); *p < 0.05 vs control (oneway ANOVA with Dunnett’s test). In (d) is shown
total neurite outgrowth of neurons in response to a range of IL-1β concentrations in the presence of low dose cocktail of neurotrophic growth
factors. Values are means ± SEM (n = 3 replicates); *p < 0.05 vs control (oneway ANOVA with Dunnett’s test). In (e) is shown total neurite
outgrowth for sensory neurons isolated from control or 3–5 month STZ-diabetic rats cultured for 1 day ± IL-1β (at 10 ng/ml). Cultures were
performed with or without neurotrophic factors. Values are the means ± SEM (n = 3 replicates). For control or diabetic *p < 0.05 vs control (Ctl)
and **p < 0.05 vs Ctl (two-way ANOVA with Bonferroni’s test).
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rons were cultured for 24 h with low dose of neurotrophic
factors, in the presence or absence of IL-1β at 10 ng/ml.
Cultures were fixed, stained for IL-1 receptor type 1 or P-
STAT3-Tyr705 and neuron-specific β-tubulin III (Figure 2).Immunocytochemical staining for the IL-1 receptor type 1
revealed that all neuronal sizes expressed the receptor
with no evidence of non-neuronal expression (Figure 2b,
d and f). Expression of the IL-1 receptor type 1 by cul-
tured neurons was not significantly altered by treatment
Figure 2 Immunocytochemical staining for the IL-1 type 1 receptor and P-STAT3-Tyr705 in control neurons. DRG sensory neurons from
normal rats were cultured for 1 day in the presence of low dose of neurotrophic growth factors and were fixed and immunostained with (a, g)
no primary antibody, or stained for (b) IL-1 type 1 receptor antibody or (c) β-tubulin III or (h) P-STAT3-Tyr705 or (i) β-tubulin III. Cultures were
also treated for 24 h with IL-1β (10 ng/ml) and stained for (d) IL-1 type 1 receptor or (e) β-tubulin III or (j) P-STAT3-Tyr705 or (k) β-tubulin III. (f)
and (l) are merge of (d+e) and (j+k) with secondary staining for neuron-specific β-tubulin III. The white arrows indicate co-localization of IL-1
type 1 receptor or P-STAT3-Tyr705 with neuron-specific staining. The bar = 100 μm. (m) Western blot for IL-1 type 1 receptor comparing control
and treated with IL-1β cultures for 30 minutes in vitro with quantification. Expression levels are expressed relative to T-ERK and are means ± SEM
(n = 3 replicates); no significant difference between Ctrl and +IL-1β.
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elevated IL-1 receptor type 1 in response to IL-1β (indi-
cated by white arrows in Figure 2d-f). Background stain-
ing for P-STAT3-Tyr705 was very low in control cultures
but was expressed in all neurons (Figure 2h and j). Treat-
ment with IL-1β caused an increase in P-STAT3-Tyr705
staining (Figure 2j and k). In Figure 2m we used Western
blotting to confirm that neurons expressed the IL-1 re-
ceptor type 1 and that expression was not significantly
affected by IL-1β treatment.IL-1β activates the JAK/STAT pathway
The ability of IL-1β to stimulate the JAK/STAT pathway
in cultured adult sensory neurons was tested using
quantitative Western blotting. DRG tissues from control
and diabetic mice were homogenized and Western blot-
ted for STAT3 phosphorylation on Tyr705 and Ser727.
Levels of STAT3 phosphorylation on Tyr705 and Ser727
were significantly diminished in diabetic compared to
control mice when normalized to T-ERK (the expression
of T-ERK is never affected by the diabetic state in DRG;
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relative to T-STAT3, however, P-STAT3-Tyr705 was not
altered (Figure 3b). Levels of T-STAT3 relative to T-ERK
did not change in diabetes. Adult DRG sensory neurons
derived from normal and diabetic rats were cultured for
24 h and treated with 10 ng/ml IL-1β for 30 min and
neurons were lysed and levels of phosphorylated STAT3
on Tyr705 and Ser727 were determined (Figure 3c and e).
IL-1β induced an approximate 1.5 to 2-fold increase in
P-STAT3-Tyr705 or Ser727 phosphorylation at 30 min
(Figure 3f ) in diabetic cultures when presented relative
to T-ERK or T-STAT3. We did not see any significant
effect of IL-1β on STAT3 phosphorylation on either epi-
tope in control cultures at 30 min, however, there was a
trend towards a 25-40% increase (Figure 3d). Note in
Figure 3e (and 4e later) that T-ERK signal revealed only
one band. This was due to changes in lot number of
antibody from the commercial source. In our hands, the
42 or 44 kDa ERK bands never exhibit any differential
change in expression under a variety of conditions
in vivo and in vitro.Figure 3 STAT3 phosphorylation is impaired in DRG in diabetes and e
of DRG samples from control and 5 month STZ-diabetic mice. In (b) expres
STAT3 and are means ± SEM (n = 3–4 mice) *P < 0.05 vs control. In (c and
diabetic rats cultured for 1 day at low dose of neurotrophic growth factors
are bar charts showing levels of phosphorylation of STAT3 on Ser-727 (Ser)
0.05 vs untreated. Values are mean ± SEM, n = 4 (two-way ANOVA with Bo
relative to T-ERK.IL-1β modulates neurite outgrowth via JAK/STAT pathway
The involvement of the JAK/STAT signal transduction
pathway in IL-1β -directed neurite outgrowth was tested
by treating with the well characterized JAK inhibitor,
AG490. In the presence of low dose of neurotrophins, cul-
tures from normal and diabetic rats were treated with
10 μM AG490 and impact on IL-1β dependent neurite
outgrowth assessed. AG490 treatment alone had little ef-
fect on neurite outgrowth in the absence of IL-1β at 24 h.
In the presence of 10 ng/ml of IL-1β, there was a 3-fold
elevation in neurite outgrowth that was completely
blocked by AG490 (Figure 4a and b). Another approach to
demonstrate the involvement of the JAK/STAT pathway
was to over-express shRNA to STAT3. DRG cells were in-
fected with lentivirus carrying scramble (scr) or shRNA to
STAT3 for 48 h and stimulated with IL-1β at 10 ng/ml for
12 hrs. Figure 4e and f shows a significant but not
complete decrease in STAT3 expression in the presence of
shRNA to STAT3. Treatment with shRNA to STAT3 sig-
nificantly, but not completely, blocked the augmentation
of neurite outgrowth induced by IL-1β (Figure 4c and d).nhanced by IL-1β in neuron cultures. In (a) is shown Western blot
sion levels are indicated and are presented relative to T-ERK or T-
e), are shown representative Western blots of DRG from normal or
and stimulated for 30 minutes with IL-1β at (10 ng/ml). In (d and f)
or Tyr-705 (Tyr) presented relative to total ERK or total STAT3. *P <
nferroni’s test). Bar charts b, d, and e also show total STAT3 levels
Figure 4 Blockade of STAT3 signaling inhibits IL-1β-mediated neurite outgrowth. DRG sensory neurons from normal and diabetic rats were
cultured for 1 day in the presence of low dose neurotrophic growth factors (to improve viability in presence of AG490) and were exposed to the
JAK/STAT inhibitor AG490 (10 μM) ± IL-1β (10 ng/ml). Neurons were fixed and stained for neuron-specific β-tubulin III. Images are shown with (a)
no treatment, DRG cultures treated with IL-1β for 24 h or treated with AG490 for 1 h then stimulated with IL-1 β for 24 h. In (b) is shown the
impact on total neurite outgrowth in control and diabetic rat cultures. Data are mean ± SEM (n = 3 replicates); *p < 0.05 vs control, or AG490, or
AG490+ IL-1β (two-way ANOVA with Bonferroni’s test). In (c and d) is shown total neurite outgrowth levels of DRG cultures from normal rats
transfected with plasmids carrying GFP and scramble sequence (scr) or STAT3 shRNA for 48 h and then stimulated with IL-1β (10 ng/ml) for 24 h.
Neurite outgrowth was derived from mean pixel area of the GFP signal captured from live cells under confocal microscopy. Data are mean ±
SEM (n = 3 replicates); *p<0.05 vs scr + IL-1β, **p<0.05 vs scr + IL-1β, ***p<0.05 vs scr + IL-1β ( oneway ANOVA with Dunnett’s test). In (e)
Western blot from DRG cultures studied in (c,d) that were analyzed for T-STAT3 and T-ERK protein. In (f) quantification of expression levels of T-
STAT3/T-ERK are expressed and are means ± SEM (n = 4 replicates); *p<0.05 vs scrambled or scrambled + IL-1β ( oneway ANOVA with Dunnett’s test).
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outgrowth in cultured adult sensory neurons
We cultured adult rat DRG sensory neurons for 24 h
with low dose neurotrophic factors in the presence or
absence of IL-1β at 10 ng/ml. Cultures were fixed andstained using anti-IL-1β antibody and antibody to neuron-
specific β-tubulin III (Figure 5a). Immunocytochemical
staining for IL-1β revealed that the majority of DRG neu-
rons expressed IL-1β in the control rat cultures. To inhibit
endogenous IL-1β activity, cultured DRG neurons were
Figure 5 DRG sensory neurons express IL-1β and its blockade inhibits neurite outgrowth. In (a) DRG sensory neurons from normal rats
were cultured for 1 day in the presence of low dose of neurotrophic growth factors and were fixed and immunostained for IL-1β. Top panels are
untreated cells and bottom panels are treated with IL-1β (10 ng/ml) for 24 h. The right panels are co-stained for β-tubulin III. In (b) DRG cultures
were infected with GFP-expressing lentivirus containing scrambled (scr) or shRNA to IL-1β. After 48 h of culture images of GFP fluorescence were
acquired and neurite outgrowth quantified. Data are mean ± SEM (n = 3 replicates); *p<0.05 vs shRNA-IL-1β (Student’s t-Test). In addition, in (c)
infected cultures were examined by Western blot for IL-1β expression and P-STAT3-Tyr and revealed significantly reduced expression in presence
of shRNA to IL-1β. In (d) DRG neurons over-expressed shRNA to IL-1β for 48 h and then were treated ± IL-1β. Neurons were stimulated with/
without IL-1β for 24 h and then neurite outgrowth quantified. Data are mean ± SEM (n = 3 replicates); *p < 0.05 vs shRNA for IL-1β + IL-1β
(Student’s t-Test). In (e) IL-1β treatment for 24 h up-regulates IL-1β luciferase promoter activity in cultured DRG sensory neurons. Co-transfection
with plasmid expressing GFP and carrying shRNA to IL-1β blocked the effect of exogenous IL-1β. Data are mean ± SEM (n = 3 replicates); *p<0.05
vs all groups (oneway ANOVA with Dunnett’s test).
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bled or shRNA for IL-1β (Figure 5b). GFP fluorescence
signal was used to quantify axonal outgrowth, demonstrat-
ing that neurite outgrowth in neurons over-expressing
shRNA to IL-1β was significantly decreased (Figure 5b).We also examined the knockdown effect of shRNA to IL-
1β on IL-1β and P-STAT3-Tyr705 expression in DRG cul-
tures by Western blot (Figure 5c). The delivery of shRNA
to IL-1β was very effective in lowering endogenous IL-1β
and P-STAT3-Tyr705 expression in these cultures. In
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and stimulated with IL-1β for the final 12 h there was a
significant effect of exogenous IL-1β on neurite outgrowth
(Figure 5d). Another approach was to use promoter re-
porter technology to study IL-1β transcriptional activity.
IL-1β promoter reporter construct (IL-1β-Luc-pr) and/or
shRNA to IL-1β were simultaneously transfected into
adult sensory neuron cultures and luciferase activity
assessed after 48 h. A sub-group of cultures were treated
with 10 ng/ml of IL-1β for the final 12 h. Figure 5e shows
that IL-1β raised IL-1β promoter activity by approximately
2-fold and shRNA to IL-1β significantly decreased this ac-
tivity suggesting auto-regulation of IL-1β promoter.STAT3 is localized to mitochondria upon Ser727
phosphorylation triggered by IL-1β
STAT3 when phosphorylated on the Ser727 epitope lo-
calized to the mitochondria of non-neuronal and clonal
cells [28,30,31]. We determined if P-STAT3-Ser727 was
localized to the mitochondria in response to IL-1β signal-
ing. Adult rat DRG sensory neurons derived from normal
rats were cultured for 24 h with low dose of neurotrophic
factors, in the presence or absence (Figure 6) of IL-1β at
10 ng/ml. Cultures were fixed, stained for P-STAT3-Ser
727, neuron-specific β-tubulin III and Mitotracker deep
red. Background levels of P-STAT3-Ser727 staining in
control cultures were below detection threshold, however,
a small cohort (approximately 15%) of DRG neurons stim-
ulated with IL-1β exhibited significantly increased expres-
sion of P-STAT3-Ser727 compared to control. By confocal
microscopy, we showed that IL-1β induced co-localizationFigure 6 IL-1β induces co-localization of P-STAT-Ser727 with mitocho
stimulated with IL-1β (10 ng/ml) for 30 min and then live cells loaded with
Ser727 and β-tubulin III. Confocal images of control (top panels) and IL-1β
and the co-localization coefficients between P-STAT3-Ser727 and MitoTrack
for β-tubulin III) with P-STAT3-Ser727 and Mitotracker co-localization. Zeis L
threshold was set manually and a table of results was generated by the so
upon review of 163 ± 4.1 neurons for each treatment of which 25.3 ± 5.6 n
The overall coefficient for co-localization with Mitrotacker deep red for the
0.086 (as derived from the Zeiss LSM510 software).of P-STAT3-Ser727 and Mitotracker deep red in neurons
with a co-localization coefficient of 0.43 ± 0.086.Bioenergetic profile is abnormal in neurons cultured from
STZ-diabetic mice and was corrected by IL-1β
To assess the mitochondrial bioenergetics profile in sen-
sory neurons derived from DRG of 3–5 month STZ-
diabetic mice, the oxygen consumption rate (OCR) was
measured in neurons cultured for 24 h using the Seahorse
Biosciences XF24 analyzer. In Figure 7 the OCR measure-
ments in (a) control (blue), diabetic (black), or treated
with IL-1β (green) at the 1 μM concentration of FCCP
were plotted. Maximal respiration (d-e), coupling effi-
ciency (c/a), respiratory control ratio (d/b) and spare re-
spiratory capacity (d–a) in (b) are presented for control
(blue), diabetic (black) and diabetic treated with IL-1β
(green) and were calculated after subtracting the non-
mitochondrial respiration (e) as described [41]. The coup-
ling efficiency is determined from the change in basal
respiration rate on addition of oligomycin. It is sensitive to
changes in all bioenergetics modules. The respiratory con-
trol ratio is the ratio of the uncoupled rate to the rate with
oligomycin and is sensitive to changes in substrate oxida-
tion and proton leak. Spare respiratory capacity indicates
how close a cell is to its bioenergetics limit when the cells
are operating under stress and/or maximal metabolic flux.
The maximal OCR induced by the uncoupler FCCP
(1 μM) in neurons cultured from diabetic mice was sig-
nificantly decreased compared to age-matched control
mice and improved by IL-1β (10 ng/ml) in diabetic neu-
rons treated for 24 h (Figure 7a). The significantndria in cultured DRG sensory neurons. DRG neurons were
MitoTracker deep red and then fixed and co-stained for P-STAT3-
stimulated neurons (bottom panels) showing the individual channels
er deep red are shown. White arrows indicate neurons (e.g. positive
SM510 software was used to measure the co-localization coefficient; a
ftware, as described previously [68]. Co-localization analysis was based
eurons (n=3 replicates) exhibited high expression of P-STAT3-Ser727.
high expressing P-STAT3-Ser727 neurons was calculated as 0.432 ±
Figure 7 Mitochondrial bioenergetics is abnormal in cultured neurons from diabetic mice and is corrected by IL-1β. OCR was measured
at basal level with subsequent and sequential addition of oligomycin (1 μM), FCCP (1 μM), and rotenone (1 μM) + antimycin A (AA; 1 μM) to DRG
neurons cultured from age-matched control (blue) and 3–5 month STZ-induced diabetic mice (black) in the presence of low dose neurotrophic
growth factors. Data are expressed as OCR in pmol/min for 1000 cells (there were approximately 2500–5000 cells per well). Dotted lines, a–e in
(a) have been used later for quantification of bioenergetics parameters. The OCR measurements in (a) control (blue), diabetic (black), or treated
with IL-1β (green) at the 1 μM concentration of FCCP were plotted. Maximal respiration (d-e), coupling efficiency (c/a), respiratory control ratio
(d/b) and spare respiratory capacity (d–a) in (b) are presented for control (blue), diabetic (black) and diabetic treated with IL-1β (green) and were
calculated after subtracting the non-mitochondrial respiration (e) as described [41]. Values are mean ± SEM of n = 5 replicate cultures; *p < 0.05
by Student’s t-Test.
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indicative of suboptimal spare respiratory capacity in
diabetic neurons compared with age matched controls.
Neurons from diabetic mice cultured with IL-1β for
24 h exhibited significantly improved maximal respir-
ation, coupling efficiency (very small impact and pos-
sibly physiologically irrelevant), respiratory control ratio
and spare respiratory capacity (Figure 7b). Inhibition of
the JAK/STAT pathway induced by AG490 (10 μM) for
24 h significantly suppressed maximal respiration rates,
coupling efficiency, respiratory control ratio and spare
respiratory capacity in IL-1β treated diabetic neurons
(Figure 8a,b). In DRG cultures from normal rat treatmentwith IL-1β caused a small but reproducible increase in
maximal respiration and spare respiratory capacity
(see legend to Figure 8). This correlated with the small
increases in P-STAT3 induced by IL-1β in control cul-
tures (Figure 3d).
Discussion
We discovered for the first time that IL-1β expression
was reduced in sensory neurons and peripheral nerve in
diabetes. The generalized down-regulation of cytokine
expression seen both in the present study and previously
[40] clearly shows that an inflammatory environment is
not triggered in the DRG or nerve during early stages of
Figure 8 Mitochondrial bioenergetics in cultured neurons from
diabetic mice is abnormal when it is treated with AG490. OCR
was measured in the same conditions as Figure 7. DRG neurons
were cultured from 3–5 month STZ-induced diabetic mice treated
with IL-1β (green) or from 3–5 month STZ-induced diabetic mice
treated with AG490 for 1 hr than stimulated with IL-1β (red) in the
presence of low dose neurotrophic growth factors. Data are
expressed as OCR in pmol/min for 1000 cells (there were
approximately 2500–5000 cells per well). The OCR measurements in
(a) diabetic treated with IL-1β (green) or diabetic treated with
AG490 for 1 hr than stimulated with IL-1β (red) at the 1 μM
concentration of FCCP were plotted. Bioenergetic parameters were
determined as described in Figure 7 and presented in (b) for DB+IL-
1β (green), DB+AG490+IL-1β (red). Values are mean ± SEM of n = 5
replicate cultures; *p < 0.05 by Student’s t-Test. Control cultures
were treated with IL-1β for 24 hr and revealed increases in maximal
respiration; control, 159.8 ± 11.7 vs IL-1β, 299.5 ± 70.0 and spare
respiratory capacity; control, 116.5 ± 16.6 vs IL-1β, 191.0 ± 44.0.
Values are means ± SEM, n=2-4, and expressed as pMoles/min
normalized to neuron number (per 5000 cells).
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present study was to investigate the signal transduction
pathways utilized by IL-1β in regulating neurite out-
growth in adult sensory neurons. By understanding these
events we hope to identify novel drug targets for therapy
in diabetic neuropathy, a severe neurodegenerative dis-
ease involving impaired axonal plasticity. The results
show that IL-1β augmented neurite outgrowth, in part,
through the JAK-STAT3 pathway (the activity of this
pathway was impaired in DRG isolated from diabetic an-
imals). Blockade of JAK-STAT3 signaling using pharma-
cological inhibition or shRNA to STAT3 significantly
reduced IL-1β dependent neurite outgrowth. We also
uncovered a novel autocrine pathway whereby endogen-
ous neuronal IL-1β enhanced neurite outgrowth. Finally,
mitochondrial function was impaired in neurons derived
from diabetic mice and could be up-regulated by IL-1β
treatment through a JAK-STAT dependent pathway.
In the peripheral nervous system other groups have
shown that IL-1β can promote neurite outgrowth from
DRG neurons. In organ culture of adult DRG IL-1β en-
hanced axon regeneration [42]. In dissociated rat sensory
neurons from postnatal day 9–10 treatment with IL-1β
increased neurite outgrowth via p38 MAPK activation
[6]. Delivery of IL-1β by miniosmotic pump for 2 weeks
to the crushed sciatic of rats was able to accelerate axon
regeneration as measured using morphological and func-
tional criteria [15]. IL-1β knockout mice exhibit reduced
functional recovery, specifically locomotor function, fol-
lowing nerve crush although IL-1β clearly has several
complementary roles at the crush site including mediat-
ing neutrophil biology and hyperalgesia [7]. Combined
with this previous literature our study reveals that treat-
ment with the cytokines IL-1α and β enhanced neurite
outgrowth via direct effects on cultured neurons. Neu-
rons derived from normal or diabetic rats were able to
respond to IL-1β with effects of IL-1β more pronounced
in the absence of neurotrophic factors. This data pro-
vides encouraging evidence that in vivo treatment of
damaged nerves in the setting of diabetes can be effect-
ive in enhancing axonal plasticity and ideally augmenting
levels of distal nerve fibers in the skin (the primary site
of fiber loss in diabetes) [43,44].
Our studies focused on IL-1β dependent signaling via
the JAK-STAT3 pathway. During development of the
nervous system STAT3 plays an important role in axon
pathfinding, neurite outgrowth and glial cell differenti-
ation [45]. In rodents, STAT3 expression is detected in
neurons and glia from embryonic day 14 to postnatal in
rat brain [46]. STAT3 is an interesting transcription fac-
tor in the context of axon regeneration in the peripheral
nervous system. STAT3 expression and phosphorylation
on Tyr-705 was enhanced in neurons and proximal
nerve following crush injury [22,23]. Intriguingly, STAT3
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occurs in the axons and perikarya of DRG neurons after
peripheral, but not central lesion, strongly supporting a
role for STAT3 in sensory axon regeneration [18,19,23].
cAMP through induction of neuropoietic molecules
such as IL-6, LIF and CNTF activates STAT3 (phosphor-
ylated on Tyr-705) as a component of a conditioning
injury in the DRG [47]. The appearance of P-STAT3-
Tyr705 in the perikarya is a dual leucine zipper kinase
(DLK) and JIP3 dependent process involving retrograde
transport of activated STAT3 from the site of injury [48].
Activated STAT3 within the perikarya initiates a range
of transcriptional changes that drives peripheral axon re-
generation (reviewed by [2,49]). In addition, activation of
STAT3 within the axon can afford neuroprotection from
axotomy-induced axonal degeneration [50]. Our work
reveals that STAT3 can be activated rapidly by IL-1β
in vitro and the process of activation involves phosphor-
ylation on Tyr-705. Furthermore, for the first time in
adult primary neurons we show that phosphorylation on
Ser-727 occurs (which could be linked to IL-1β mediated
optimization of mitochondrial bioenergetics – see later).
Sensory neurons of the DRG express IL-1β although
ability to secrete the protein remains unclear [12]. We
show that cultured sensory neurons expressed IL-1β and
exhibited endogenous transcriptional activity for the IL-
1β promoter (Figure 5). Blockade of endogenous IL-1β
reduced neurite outgrowth thus revealing for the first
time an autocrine pathway for local control of axonal
plasticity by endogenous IL-1β in adult neurons. Table 1
shows that endogenous IL-1β expression was reduced in
DRG and nerve of diabetic animals. In CNS neurons, IL-
1β enhances expression and secretion of IL-6 and GDNF
[51-54] so that down-regulation of IL-1β expression in
diabetes could trigger a generalized sup-optimal neuro-
trophic environment. The down-regulation of cytokine
gene expression and synthesis is an early target of diabetes
that is likely to have pathogenic consequences [55].
The diabetes-induced impairments in IL-1β signaling
were linked to aberrant mitochondrial bioenergetics. We
used Seahorse Biosciences XF24 analysis to measure cell
respiratory control, recording rate of ATP production,
proton leak, coupling efficiency, maximum respiratory
rate, respiratory control ratio and spare respiratory cap-
acity [41]. Measurements of oxygen consumption rate in
the presence of uncoupler revealed that the maximal
electron transport capacity was significantly depressed in
sensory neurons from STZ-diabetic mice. In our study,
phosphorylation of the STAT3 on Ser-727 and the neur-
onal mitochondrial bioenergetics profile were impaired
in DRG of STZ-diabetic mice and rats and this was pre-
vented by IL-1β treatment. We believe these defects in
mitochondrial function detected by our bioenergetics
analysis were not due to a general loss of mitochondrialnumber or mass in the cultured cells since our previous
work reveals no loss of mitochondrial mass [38,39,56].
This data complements our recent findings that diabetes
induces mitochondrial abnormalities and dysfunction in
sensory neurons in type 1 diabetes [33,38,39,56] and
reviewed [33]. Data in Figures 3 and 6 show that STAT3
phosphorylation on Ser-727 was impaired by diabetes
and enhanced by IL-1β treatment. In Figure 6 we show
localization of P-STAT3-Ser727 to the mitochondria.
Previous work shows that STAT3 is involved in cellular
respiration by regulating the activity of mitochondrial com-
plexes I and II of the electron transport system when phos-
phorylated on Ser727 [28,30,31]. STAT3 was observed to
localize in mitochondria and interact with complex I com-
ponents and GRIM 19 [57,58]. The mitochondrial activity
of STAT3 was confined to serine phosphorylation at pos-
ition 727, as overexpression of mutant STAT3-S727A in
STAT3 −/− cells did not restore the mitochondrial com-
plex I activity [28]. Thus, activated STAT3 targets multiple
sites within the axon, including the microtubule network
[50] and mitochondria [31], to optimize function and en-
hance axonal plasticity subsequent to damage.
Conclusions
This study demonstrates a novel role for of IL-1β in pre-
venting the diabetic phenotype of sensory neurons. This
work confirms previous studies demonstrating diabetes-
induced reductions in peripheral nerve tissue of cytokines
such as IL-6, TNFα and CNTF [40,59,60]. The mechanism
of action of IL-1β was mediated, in part, via optimization
of mitochondrial bioenergetics through the JAK/STAT
pathway, possibly encompassing a novel pathway linked to
STAT3 modulation of mitochondrial function. We propose
that a generalized down-regulation of cytokine expression
leading to sub-optimal axonal plasticity at distal nerve sites
contributes to development of sensory neuropathy in early
stages of experimental diabetes.
Materials and methods
Induction of type 1 diabetes in rodents
Male Sprague Dawley rats were made diabetic with a
single intraperitoneal injection of 75 mg/kg streptozoto-
cin (STZ; Sigma, St Louis, MO, USA) and male outbred
Swiss Webster mice were made diabetic by injection of
90 mg/kg STZ on two consecutive days, with each injec-
tion preceded by a 12 h fast. Only animals with blood
glucose levels of > 19 mM at the start and end of the
study were retained as diabetic. Sensory neuropathy was
confirmed in rodents at 2 months using loss of thermal
sensitivity as a marker (data not shown). Tissue was col-
lected from rodents after 2–5 months of diabetes. Animal
procedures followed guidelines of University of Manitoba
Animal Care Committee using Canadian Council of
Animal Care rules.
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DRG from adult male rats or mice were dissociated using
previously described methods [61-63]. Neurons were cul-
tured in defined Hams F12 media in the presence of
modified Bottensteins N2 supplement without insulin
(0.1 mg/ml transferrin, 20 nM progesterone, 100 mM
putrescine, 30 nM sodium selenite 1.0 mg/ml BSA; all ad-
ditives were from Sigma, St Louis, MO, USA; culture
medium was from Life Technologies, Grand Island, NY,
USA). In some experiments the media was also supple-
mented with a low dose cocktail of neurotrophic factors
(0.1 ng/ml NGF, 1.0 ng/ml GDNF, 1.0 ng/ml NT-3, and
0.1 nM insulin – all from Promega, Madison, WI, USA).
This treatment improved viability of cultures and
attempted to mimic the levels of neurotrophic support
experienced in vivo by sensory neurons. Normal neu-
rons were cultured in the presence of 10 mM glucose
and 0.1 nM insulin and diabetic neurons with 25 mM
glucose and zero insulin. Recombinant human IL-1β
and recombinant human IL-1α were obtained from
Peprotech (Cedarlane, USA). Rabbit anti-rat IL-1β anti-
body was from Millipore (CA, USA). AG490 was pur-
chased from Millipore (Canada).
Measurement of cytokine protein levels using Luminex
system
Levels of cytokines (IL-1α, IL-1β, IL-10 and IL-2) were
measured using a Bio-Plex Rat 9-Plex kit (Bio-Rad,
Hercules, CA, USA) according to manufacturer’s instruc-
tions. Studies on rats were performed to ensure enough
protein for detection. Lumbar DRG, mid sciatic nerve and
tibial nerve tissue samples from control and STZ-induced
diabetic rats were homogenized on ice with a polytron in
the presence of Tissue Extraction Reagent I (Invitrogen,
#FNN0071A). Multiplex beads were added to each well of
a 96-well plate and 100 μl of either the standards or ho-
mogenized samples were added, agitated for 30 min then
washed 3 times. Beads were incubated with the detection
antibodies for 30 min and data were quantified on a Bio-
Rad Bioplex 200 Luminex system and analyzed with asso-
ciated software (Bio-Rad, Hercules, CA, USA). Samples
were assayed in triplicate, while cytokine standards were
in duplicate. A minimum of 100 beads per analyte was
used and the levels (pg/mg) of the cytokines were calcu-
lated from the standard curve and corrected to the protein
concentration.
shRNA knockdown of gene expression in DRG neurons
For shRNA-based gene silencing, GFP expressing clones
specific for IL-1β and STAT3 (clone Id: V3LMM_471275
and V3LMM_424801, respectively) were obtained from
OpenBiosystems (Lafayatte, CO, USA). The pGIPz lenti-
viral system from the OpenBiosystems database is held at
University of Manitoba, Winnipeg, Canada. A controlscrambled shRNA unrelated to IL-1β and STAT3 se-
quence was used as a negative control for lentiviral trans-
duction and plasmid transfection [64]. For gene silencing
studies that were focused on determination of gene ex-
pression rat DRG cells were transduced with lentivirus at
20X infectious unit in the presence of polybrene (8 μg/ml)
for 2 h at 37°C, complete medium was added and neurons
cultured for additional 48 h. For neurite outgrowth studies
neurons were transduced with lentivirus or transfected
with plasmid (as described in next section). Fluorescence
images derived from GFP-expressing virally transduced or
plasmid transfected neurons were acquired by using a
LSM510 confocal microscope (Carl Zeiss) with 20X air
objective.Luciferase reporter constructs for IL-1β and cell
transfection
Reporter plasmid with the IL-1β promoter upstream from
luciferase was kindly donated by Dr. Jian Fei (Shanghai
Research Center for Model Organisms, Shanghai, China)
[65]. Rat DRG cells (30×103) were transfected in triplicate
with 1.8 μg of IL-1β Luc-promoter plasmid DNA and
0.2 μg of pCMV-Renilla (Promega, Madison, WI, USA)
using the Amaxa Nucleofector electroporation kit for low
numbers of cells according to the manufacturer’s instruc-
tions (ESBE Scientific, Toronto, ON, Canada). In some
experiments co-transfection was performed with plasmid
carrying shRNA to STAT3 (clone ID: V3LMM_424801)
or shRNA to IL-1β (clone ID: V3LMM_471275) ob-
tained from OpenBiosystems (Lafayatte, CO, USA).
Cells were lysed using passive lysis buffer provided with
the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA). The luciferase activity was mea-
sured using a luminometer (model LMAXII; Molecular
Devices, Sunnyvale, CA, USA). 20 μl of each sample was
loaded in a 96-well plate and was mixed with 100 μl of
Luciferase Assay Reagent II and firefly luciferase activity
was first recorded. Then, 100 μl of Stop-and-Glo Reagent
was added, and Renilla luciferase activity was measured.
All values are normalized to Renilla luciferase activity. For
lentiviral infection or plasmid transfection cultures of rat
cells were preferred due to high cell yields.Quantification of neurite outgrowth
GFP-based or immunostaining-based fluorescent images
were captured and the mean pixel area determined using
ImageJ software (adjusted for the cell body signal). All
values were normalized for neuronal number. In this
culture system the level of total neurite outgrowth has
been previously validated to be directly related to an ar-
borizing form of axonal plasticity and homologous with
in vivo collateral sprouting [66]. Studies were performed
with rat cultures due to higher cell yields.
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Cultured DRG neurons from adult rats were harvested
after 24 h or intact lumbar DRG from adult mice were
rapidly isolated and then homogenized in ice-cold
stabilization buffer containing: 0.1 M Pipes, 5 mM
MgCl2, 5 mM EGTA, 0.5% Triton X-100, 20% glycerol,
10 mM NaF, 1 mM PMSF, and protease inhibitor cock-
tail [67]. Proteins were assayed using DC protein assay
(BioRad; Hercules, CA, USA) and Western blot analysis
performed as previously described [39,67]. The samples
(5 μg total protein/lane) were resolved on a 10% SDS-
PAGE gel, and electroblotted (100 V, 1 h) onto a nitro-
cellulose membrane. Blots were then blocked in 5%
nonfat milk containing 0.05% Tween overnight at 4°C,
rinsed in TBS-T and then incubated with the primary
antibodies for phospho-STAT3 (Tyr705) or phospho-
STAT3 (Ser727) or T-STAT3 antibody (1:1000; Cell Sig-
naling Technology, Danvers, MA, USA) or IL-1RAcP
(1:500; Santa Cruz Biotechnologies, CA). Total ERK
(1: 1500; Santa Cruz Biotechnologies, CA) was used as a
loading control. After four washes of 10 min in TBS-T,
secondary antibody was applied for 1 h at room
temperature. The blots were rinsed, incubated in Western
Blotting Luminol Reagent (Santa Cruz Biotechnologies,
CA, USA), and imaged using the BioRad Fluor-S Max
image analyzer. For culture work source material was from
rats to ensure high enough protein yields. DRG samples
were collected from control vs diabetic mice since the
Swiss Webster mice were cheaper to maintain, reveal less
inter-animal variability and onset of neuropathy was
quicker compared with rats.
Co-localization studies and immunocytochemistry for
detection of tubulin and phospho-STAT3 (Tyr705 or
Ser727)
For co-localization experiments DRG neuron cultures
from adult rats were incubated with 500 nM Mitotracker
deep red TM (Molecular Probes, Invitrogen, USA) at 37°C
for 30 min. Cultures were fixed with 4% paraformaldehyde
in phosphate buffered saline (PBS, pH 7.4) for 15 min at
room temperature then permeabilized with 0.3% Triton
X-100 in PBS for 5 min. Cells were then incubated in
blocking buffer (Roche, Indianapolis, IN, USA) diluted
with FBS and 1.0 mM PBS (1:1:3) for 1 h then rinsed three
times with PBS. Primary antibodies used were: β-tubulin
isotype III (1:1000) neuron specific from Sigma Aldrich,
Oakville, ON, Canada; phospho-STAT3 (Tyr705 or Ser727
(1:300) Cell Signaling Technology, Danvers, MA, USA).
Antibodies were added to all wells and plates were incu-
bated at 4°C overnight. The following day, the coverslips
were incubated with FITC- and CY3-conjugated second-
ary antibodies (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) for 1 h at room temperature,
mounted and imaged using a Carl Zeiss Axioscope-2fluorescence microscope equipped with an AxioCam cam-
era. Images were captured using AxioVision3 software.
Co-localization coefficients between P-STAT3-Ser727 and
MitoTracker deep red were analyzed using confocal im-
aging with Zeiss LSM510 software and followed proce-
dures previously described [68].
Measurement of mitochondrial respiration in cultured
DRG neurons from mice
An XF24 Analyzer (Seahorse Biosciences, Billerica, MA,
USA) was used to measure neuronal bioenergetic func-
tion. The XF24 creates a transient 7 μl chamber in
specialized 24-well microplates that allows for oxygen
consumption rate (OCR) to be monitored in real time.
Culture medium was changed 1 h before the assay to
unbuffered DMEM (Dulbecco’s modified Eagle’s
medium, pH 7.4) supplemented with 1 mM pyruvate,
and 10 mM D-glucose. Neuron density in the range of
2,500-5,000 cells per well gave linear OCR. Oligomycin
(1 μM), carbonylcyanide-p-trifluoromethoxyphenylhydra-
zone (FCCP; 1.0 μM) and rotenone (1 μM) + antimycin A
(1 μM) were injected sequentially through ports in the
Seahorse Flux Pak cartridges. Each loop was started with
mixing for 3 min, then delayed for 2 min and OCR mea-
sured for 3 min. This allowed determination of the basal
level of oxygen consumption, the amount of oxygen
consumption linked to ATP production, the level of
non-ATP-linked oxygen consumption (proton leak), the
maximal respiration capacity and the non-mitochondrial
oxygen consumption [41,69]. Oligomycin inhibits the ATP
synthase leading to a build-up of the proton gradient that
inhibits electron flux and reveals the state of coupling effi-
ciency. Uncoupling of the respiratory chain by FCCP in-
jection reveals the maximal capacity to reduce oxygen.
Finally, rotenone + antimycin A were injected to inhibit
the flux of electrons through complexes I and III, and thus
no oxygen was further consumed at cytochrome c oxidase.
The remaining OCR determined after this intervention is
primarily non-mitochondrial. Following OCR measure-
ment the cells were immediately fixed and stained for
β-tubulin III as described above. The plates were then
inserted into a Cellomics Arrayscan-VTI HCS Reader
(Thermo Scientific, Pittsburgh, PA, USA) equipped with
Cellomics Arrayscan-VTI software to determine total
neuronal number in each well. Data are expressed as
OCR in pmoles/min for 1,000 cells. Cultures from con-
trol vs diabetic mice were used since the Swiss Webster
mice were cheaper to maintain, reveal less inter-animal
variability and onset of neuropathy was quicker com-
pared with rats.
Statistical analysis
Where appropriate, data (presented as mean ± SEM) were
subjected to one-way ANOVA with post-hoc comparison
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Tukey’s tests or regression analysis with a one-phase expo-
nential decay parametric test with Fisher’s parameter
(GraphPad Prism 4, GraphPad Software Inc., San Diego,
CA). Where appropriate two-way ANOVA was performed
with Bonferronis post hoc test. In all other cases two-
tailed Student’s t-Tests were performed.
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